Kolon TissueGene is a biopharmaceutical company based in Maryland that specializes in the development of advanced cell therapies for orthopedic disorders and unmet medical needs. Their flagship product, TG-C, is an allogeneic cell and gene therapy designed to effectively treat osteoarthritis of the knee by reducing pain, increasing function, and slowing disease progression.
With a focus on targeting various orthopedic diseases and degenerative disorders, Kolon TissueGene is dedicated to providing innovative solutions for patients suffering from these conditions. Through their platform technology, they aim to revolutionize the treatment of osteoarthritis and improve the quality of life for individuals affected by this debilitating disease.
Generated from the website